Delivering the Cures

Hunterian Medicine is a gene editing company poised to unleash the full potential of CRISPR.  Our patented platform technology solves the CRISPR delivery problem by enabling efficient, on-target delivery through a single adeno-associated virus (AAV). The Hunterian Technology opens an immediate path to develop cures for a vast number of genetic diseases where no FDA approved therapies exist.

Read our latest Press Release
Download the PDF

Hunterian featured in Chemical & Engineering News!


Our Story

Hunterian’s mission is to cure genetic diseases by correcting DNA mutations using its innovative CRISPR delivery technology.


Every year, nearly 8 million children are born with genetic diseases caused by mutations in DNA. There are 6,000-7,000 known genetic disorders – examples include ALS, cystic fibrosis, muscular dystrophy, or Fuchs’ dystrophy. For over 95% of these diseases, no FDA-approved treatments or cures exist. 

CRISPR is a revolutionary gene-editing tool with the ability to edit nearly any DNA sequence within the human genome, and the potential to correct a multitude of disease-causing mutations. While traditional medical research has focused on developing pharmaceuticals to treat the symptoms of genetic disorders, correcting DNA mutations directly could provide permanent, one-time cures.

However, the clinical promise of CRISPR is limited by the absence of a safe and effective method to deliver the genome-editing technology into cells within the human body (in vivo). The Hunterian technology uses a novel genetic element to enable in vivo delivery via a single adeno-associated virus (AAV).


Hunterian’s patented technology overcomes the delivery problem that has been the most significant barrier to the widespread development of therapeutics using CRISPR.


Our Technology

Many scientists believe the key to unlocking CRISPR’s therapeutic potential is delivery via an adeno-associated virus (AAV), an FDA-approved delivery vehicle with a history of safety, efficacy, and lack of toxicity. Until now, the small size of AAV has been a significant obstacle for the packaging of CRISPR, leaving less safe and less effective therapeutic options.


Hunterian’s technology uses a novel “2-for-1” genetic control element, a bidirectional promoter, to overcome the challenge of delivering CRISPR via AAV. The bidirectional promoter shrinks the “instructions” necessary for in vivo expression of CRISPR, thereby enabling CRISPR delivery well within the limited AAV packaging capacity.

By freeing up critical space in AAV, Hunterian's technology allows for the development of the safest and most effective CRISPR-based therapeutics.  Hunterian's approach has the immediate potential to bring multiple CRISPR technologies to the clinic and dramatically accelerate the development of CRISPR-based therapeutics. 

Our platform technology enables scientists to target far more regions in the human genome – over a BILLION more than existing technologies – meaning that many more mutations in skeletal or cardiac muscle, lungs, brain, and other tissues can now be addressed using CRISPR technology.



Our platform technology enables scientists to target over a billion more regions in the human genome than any existing technology.


Contact Us

Hunterian is headquartered in Cambridge, Massachusetts.


For general information:

For licensing or partnering opportunities:

For career opportunities:

For media requests: 
Erik Clausen at or
Mark Button at